Technology Listings


Stem Cell-Based Therapy for Vascular Disease

Application

A device and kit for isolating therapeutic quantities of vasculgenic cells from blood that acts as an autologous adult stem cell therapy for the treatment of limb ischemia, ischemic heart disease, and other vascular-related disorders.

Key Benefits
  • Reduces complexity and expense of current autologous stem cell therapies.
  • Cells can be isolated and transplanted at the point of care without expanding in culture.
  • Isolation & sorting of stem cells uses currently available cell-sorting technology.
  • Uses a novel cell surface marker to isolate endothelial progenitor cells (EPCs, blood vessel forming cells) from peripheral blood. 
Technial Summary

Recent advances in stem cell therapy have demonstrated the viability of bone marrow-derived stem cells for regrowing vasculature and restoring blood flow after an ischemic event. The biggest hurdle to these therapies has been the inability to efficiently identify, isolate, and sort-out EPCs from samples in quantities sufficient for transplantation. Currently isolated EPCs must be removed and cultured before transplant, which adds expense, time, and the possibility of contamination to EPC transplant therapy. Emory inventor Dr. Young-sup Yoon has devised a novel method for isolating EPCs directly from peripheral blood by employing a new cell surface marker CD31. CD31+ EPCs that are vasculogenic can be directly isolated from a patient's peripheral blood in therapeutic quantities, thus making them ideal candidates for revascularization transplants following events such as heart attacks, limb injuries or neuropathy. This discovery could serve as the basis for a device that screens and isolates EPCs on location during surgery using currently available cell-sorting technologies. This would reduce the complexity, time and expense associated with isolating EPCs used to treat vascular diseases including limb ischemia.

View our featured innovation.

Review our Breakfast Club PowerPoint

Developmental Stage

CD31+ cells isolated by this method have been demonstrated to be effective at regenerating vasculature and improving blood flow in mouse models of ischemic limb-injuries.

Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date
Nationalized PCT - United States United States 12/447,180 8,747,905 10/29/2007 6/10/2014 5/16/2029
Continuation United States 15/334,541 10/26/2016    
Tech ID: 09049
Published: 3/23/2010
Category
Therapeutics

Contact
Justin Burns
Licensing Associate
Emory University
justin.burns@emory.edu

Inventor(s)
Young-Sup Yoon
Hyun-Jai Cho

Keywords
Cardiovascular
Cell/Gene Therapy